MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Hydroxyurea (Hydrea®; Siklos®)

Selected References:

  • American Health Packaging. 2023. Hydroxyurea Product Label. National Institute of Health DailyMed database. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c84a2241-6c05-480f-8a5b-049e08c27d73#:~:text=Hydroxyurea%20capsules%2C%20USP%20is%20an,in%20combination%20with%20concurrent%20chemoradiation. [Accessed 10 Jan 2024.]
  • Ballas SK, et al. 2009. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc. 101(10):1046-1051.
  • Baykal C, et al. 2000. Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report. Eur J Gynaecol Oncol 21:89-90
  • Boafor TK, et al. 2016. Pregnancy outcomes in women with sickle-cell disease in low and high income countries: a systematic review and meta-analysis. BJOG 123:691-698.
  • Byrd DC, et al. 1999. Hydroxyurea in two pregnant women with sickle cell anemia. Pharmacotherapy 19:1459-1462.
  • Celiloglu M, et al. 2000. Hydroxyurea treatment for chronic myeloid leukemia during pregnancy. Acta Obstet Gynecol Scand. 79:803-804.
  • Charache S, et al. 1995. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332:1317-1322.
  • Cinkotai KI, et al. 1994. Pregnancy after treatment with hydroxyurea in a patient with primary thrombocythaemia and a history of recurrent abortion. J Clin Pathol 47:769-770.
  • Dell’Isola A, et al. 1997. Essential thrombocythemia in pregnancy. A case report and general considerations. Minerva Ginecol 49:165-172.
  • Delmer A, et al. 1992. Pregnancy during myelosuppressive treatment for chronic myelogenous leukaemia. Br J Haematol 82:783-784.
  • Diav-Citrin O, et al. 1999. Hydroxyurea use during pregnancy: a case report in sickle cell disease and review of the literature. Am J Hematol 60:148-150.
  • Doney KC, et al. 1979. Combination chemotherapy for acute myelocytic leukemia during pregnancy: three case reports. Cancer Treat Rep 63:369-371.
  • R. Squib & Sons, LLC. 2022. Hydrea Product Label. National Institute of Health DailyMed database. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=050bd2a2-a125-721a-e366-255c5466f018. [Accessed 10 Jan 2024.]
  • Fadilah SA, et al. 2002. Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea. Leukemia 16:1202-1203.
  • Fernandez H. 1994. [Essential thrombocythemia and pregnancy]. J Gynecol Obstet Biol Reprod 23(1):103-104.
  • Fitzgerald JM, et al. 1993. The combination of hydroxyurea and leucapheresis in the treatment of chronic myeloid leukaemia in pregnancy. Clin Lab Haematol 15:63-65.
  • Grigg A. 2007. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J 37(3):190-192.
  • Habibi A, et al. 2023. Outcomes of pregnancy in sickle cell disease patients: results from the prospective ESCORT-HU cohort study. Biomed 11(2): 597.
  • Italia KY, et al. 2010. Exposure to hydroxyurea during pregnancy in sickle-beta thalassemia: a report of 2 cases. J Clin Pharmacol. 50(2):231-234.
  • Jackson N, et al. 1993. Hydroxyurea treatment for chronic myeloid leukaemia during pregnancy. Br J Haematol 85:203-204.
  • Koh LP, et al. 2002. Four pregnancies in two patients with essential thrombocythaemia – a case report. Ann Acad Med Singapore 31:353-356.
  • Kroner BL, et al. 2022. Pregnancy outcomes with hydroxyurea use in women with sickle cell disease. Am J Hematol. 97(5): 603–612.
  • Malowski AK, et al. 2021. Distinct maternal and fetal pregnancy outcomes in women with sickle cell disease can be predicted using routine clinical and laboratory data. Brit J Haematol 194(6):1063–1073.
  • Marahatta A, Ware RE. 2017. Hydroxyurea: analytical techniques and quantitative analysis. Blood Cells Mol Dis. 67:135–142.
  • 2024. Hydroxyurea Product Label. National Institute of Health Dailymed Database. Available at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76957c0d-0f98-4376-bb06-eee651adc09d. [Accessed 14 Feb 2024].
  • National Heart, Lung, and Blood Institute. 2014. Evidence-based management of sickle cell disease: expert panel report, 2014. U.S. Department of Health and Human Services, National Institutes of Health.
  • Oskuie AE, et al. 2011. Successful outcome of pregnancy in a case of essential thrombocytosis treated with hydroxyurea. Indian J Cancer. 48(2):268-269.
  • Oteng-Ntim E, et al. 2015. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta-analysis. Blood 125:3316–3325.
  • Pata O, et al. 2004. Polycythemia vera and pregnancy: a case report with the use of hydroxyurea in the first trimester. Am J Perinatol 21:135-137.
  • Patel M, et al. 1991. Use of hydroxyurea in chronic myeloid leukemia during pregnancy: a case report. Am J Obstet Gynecol 165:565-566.
  • Pecker LH, Kuo KHM. 2022. Go the Distance: Reproductive healthcare for people with sickle cell disease. Hematol Oncol Clin North Am. 36(6): 1255–1270.
  • Rustin GJS, et al. 1984. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumours. Br Med J 288:103-106.
  • Rogers DT, Molokie R. 2010. Sickle cell disease in pregnancy. Obstetrics and gynecology clinics of North America 7(2), 223–237.
  • Saleh AJM, et al. 2014. Leukemia during pregnancy: long term follow up of 32 cases from a single institution. Hematol Oncol Stem Cell Ther 7(2): 63-68.
  • Szanto F, Kovacs L. 1993. [Successful delivery following continuous cytostatic therapy of a leukemic pregnant women]. Orv Hetil 34(10):527-529.
  • Tertian G, et al. 1992. Hydroxyurea and pregnancy. Am J Obstet Gynecol 166:1868.
  • Thauvin-Robinet C, et al. 2001. Exposure to hydroxyurea during pregnancy: a case series. Leukemia 15:1309-1311.
  • Ware RE, et al. 2020. Hydroxyurea exposure in lactation: a pharmacokinetics study (HELPS). J Pediatr. 222:236–239.
  • Wright CA, Tefferi A. 2001. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol 66: 152-159.

 

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.